OpenClaw-Medical-Skills pan-cancer-multiomics-agent

<!--

install
source · Clone the upstream repo
git clone https://github.com/FreedomIntelligence/OpenClaw-Medical-Skills
Claude Code · Install into ~/.claude/skills/
T=$(mktemp -d) && git clone --depth=1 https://github.com/FreedomIntelligence/OpenClaw-Medical-Skills "$T" && mkdir -p ~/.claude/skills && cp -r "$T/skills/pan-cancer-multiomics-agent" ~/.claude/skills/freedomintelligence-openclaw-medical-skills-pan-cancer-multiomics-agent && rm -rf "$T"
OpenClaw · Install into ~/.openclaw/skills/
T=$(mktemp -d) && git clone --depth=1 https://github.com/FreedomIntelligence/OpenClaw-Medical-Skills "$T" && mkdir -p ~/.openclaw/skills && cp -r "$T/skills/pan-cancer-multiomics-agent" ~/.openclaw/skills/freedomintelligence-openclaw-medical-skills-pan-cancer-multiomics-agent && rm -rf "$T"
manifest: skills/pan-cancer-multiomics-agent/SKILL.md
source content
<!-- # COPYRIGHT NOTICE # This file is part of the "Universal Biomedical Skills" project. # Copyright (c) 2026 MD BABU MIA, PhD <md.babu.mia@mssm.edu> # All Rights Reserved. # # This code is proprietary and confidential. # Unauthorized copying of this file, via any medium is strictly prohibited. # # Provenance: Authenticated by MD BABU MIA -->

name: 'pan-cancer-multiomics-agent' description: 'AI-powered pan-cancer analysis integrating genomic, transcriptomic, proteomic, and epigenomic data for cancer subtyping, driver identification, and cross-cancer pattern discovery.' measurable_outcome: Execute skill workflow successfully with valid output within 15 minutes. allowed-tools:

  • read_file
  • run_shell_command

Pan-Cancer Multi-Omics Agent

The Pan-Cancer Multi-Omics Agent integrates multi-omics data across cancer types to identify shared oncogenic drivers, discover novel subtypes, and enable cross-cancer therapeutic insights. It leverages TCGA, CPTAC, and other pan-cancer resources with deep learning for comprehensive cancer characterization.

When to Use This Skill

  • When analyzing patient tumors in context of pan-cancer molecular profiles.
  • To identify shared drivers and vulnerabilities across cancer types.
  • For discovering novel molecular subtypes that span histological boundaries.
  • When prioritizing therapeutic targets with pan-cancer evidence.
  • To benchmark single-cancer findings against pan-cancer patterns.

Core Capabilities

  1. Pan-Cancer Subtyping: ML-based clustering across 32+ cancer types to identify molecular subtypes transcending tissue of origin.

  2. Driver Discovery: Integrate mutation, expression, and CNV data to identify oncogenic drivers using pan-cancer statistical power.

  3. Multi-Omics Fusion: Deep learning integration of mRNA, miRNA, methylation, and protein data for comprehensive profiles.

  4. Pathway Analysis: Identify dysregulated pathways with pan-cancer prevalence and therapeutic implications.

  5. Survival Modeling: PRISM framework for multi-omics prognostic marker discovery and survival prediction.

  6. Therapeutic Matching: Map patient profiles to pan-cancer drug sensitivity data and clinical trial evidence.

TCGA Pan-Cancer Atlas Integration

Data TypeSamplesApplication
Somatic mutations11,000+Driver identification
Copy number11,000+Amplifications/deletions
mRNA expression11,000+Expression subtypes
miRNA expression10,000+Regulatory networks
DNA methylation10,000+Epigenetic subtypes
Protein (RPPA)8,000+Pathway activation

Workflow

  1. Input: Patient multi-omics data (mutations, CNV, expression, methylation).

  2. Normalization: Harmonize data to TCGA reference standards.

  3. Classification: Assign to pan-cancer molecular subtypes.

  4. Driver Analysis: Identify patient-specific drivers in pan-cancer context.

  5. Pathway Scoring: Calculate pathway activation scores.

  6. Therapeutic Matching: Identify actionable targets and trial matches.

  7. Output: Pan-cancer classification, driver report, pathway profiles, treatment recommendations.

Example Usage

User: "Classify this breast cancer patient's tumor in the pan-cancer context and identify shared drivers."

Agent Action:

python3 Skills/Oncology/Pan_Cancer_MultiOmics_Agent/pancancer_analyzer.py \
    --mutations patient_mutations.maf \
    --expression patient_rnaseq.tsv \
    --methylation patient_methylation.tsv \
    --cnv patient_cnv_segments.tsv \
    --reference tcga_pancancer \
    --subtype_method nmf_consensus \
    --output pancancer_report/

Pan-Cancer Molecular Subtypes

Cross-cancer molecular taxonomy identifies patterns beyond histology:

SubtypeCharacteristicsExample Cancers
C1-Wound healingHigh proliferation, MYC ampBreast, ovarian, bladder
C2-IFN-gamma dominantImmune active, high TCR/BCRMelanoma, lung, cervical
C3-InflammatoryNF-kB, cytokine signaturesHead/neck, stomach
C4-Lymphocyte depletedLow immune, PTEN lossGlioma, uveal melanoma
C5-Immunologically quietLow expression overallKidney chromophobe, thyroid
C6-TGF-beta dominantHigh TGF-B, fibrosisPancreas, rectum, glioma

Deep Learning Architecture

Multi-Omics Integration Model:

Input Layers:
  - Genomic encoder (mutations, CNV)
  - Transcriptomic encoder (mRNA, miRNA)
  - Epigenomic encoder (methylation)
  - Proteomic encoder (RPPA)

Fusion Layer:
  - Cross-attention mechanism
  - Multi-modal variational autoencoder

Output Heads:
  - Subtype classifier
  - Survival predictor
  - Drug response predictor

MLOmics Database Access

The agent integrates with MLOmics, providing:

  • 8,314 patient samples across 32 cancer types
  • Pre-computed features for ML benchmarking
  • Standardized train/test splits for reproducibility
  • Drug sensitivity data for 300+ compounds

Prerequisites

  • Python 3.10+
  • PyTorch with multi-modal architectures
  • Access to TCGA, CPTAC, or local data
  • 16GB+ RAM for pan-cancer analysis

Related Skills

  • Tumor_Clonal_Evolution - For intratumoral heterogeneity
  • Multi_Omics_Integration - For single-patient integration
  • Drug_Repurposing - For therapeutic matching

Clinical Applications

  1. Cancer of Unknown Primary (CUP): Identify tissue of origin
  2. Cross-indication trials: Find basket trial eligibility
  3. Driver prioritization: Pan-cancer functional evidence
  4. Prognosis: Multi-omics survival models

Author

AI Group - Biomedical AI Platform

<!-- AUTHOR_SIGNATURE: 9a7f3c2e-MD-BABU-MIA-2026-MSSM-SECURE -->